

AstraZeneca Covid-19 Vaccine Suspended Across Europe. “Possible Autoimmune Reactions, Blood Clotting, Stroke and Internal Bleeding”

By [Prof Michel Chossudovsky](#)
Global Research, March 20, 2021

Region: [Canada](#), [Europe](#), [USA](#)
Theme: [Science and Medicine](#)

UPDATE

France, Germany and Italy which had suspended the AstraZeneca vaccine, have resumed “after health officials sought to allay concerns it may cause blood clots” (VA Report)

This resumption of inoculations followed statements by the WHO and the European Medicines Agency (EMA), to the effect that the AstraZeneca vaccine was “safe and effective”.

A public relations campaign has been launched in support of the Big Pharma vaccine project]

March 20, 2021

Several European countries have now suspended the mRNA AstraZeneca Covid-19 Vaccine including:

Denmark, Norway, Iceland, Austria, Bulgaria.

And then the four most populated countries of the European Union: Germany, France, Italy, Spain,

Followed by Ireland, the Netherlands, Estonia, Slovenia, Lithuania, Luxembourg and Romania.

The total number of EU countries is now 18.

On Tuesday, March 16, Sweden and Latvia have suspended the AstraZeneca vaccine

Thailand and the Democratic Republic of the Congo (DRC) have also suspended the AstraZeneca vaccine.

On March 10, 2021, an open letter was submitted by a Collective of prominent medical doctors and scientists to the European Medicines Agency (EMA):

[Urgent Open Letter from Doctors and Scientists to the European Medicines Agency regarding COVID-19 Vaccine Safety Concerns](#) By [Doctors for COVID Ethics](#), March 10, 2021

The letter (posted on Global Research) describes:

“serious potential consequences of COVID-19 vaccine technology, warning of possible autoimmune reactions, blood clotting abnormalities, stroke and internal bleeding, “including in the brain, spinal cord and heart”.

See also the [Press Release issued by the Doctors for COVID Ethics](#)

AstraZeneca Vaccine suspension in Germany

In recent developments (March 15, 2021), Germany’s Ministry of Health has confirmed the “temporary suspension” of the AstraZeneca COVID-19 vaccine:

“The European Medicines Agency is to decide “whether and how the new information will affect the authorization of the vaccine” pending an investigation. (Deutsche Welle).

The mRNA Vaccine in the US. Pfizer-BioNTech and Moderna Inc.

Sofar the suspensions apply only to AstraZeneca which is being marketed in Europe and several other countries.

Three other major pharmaceutical conglomerates, namely Pfizer-BioNTech, Moderna Inc. and Johnson and Johnson (J & J) are involved in marketing the mRNA vaccine technology, which is categorized in the US as an “experimental” drug.

In the US, the “Green Light” to the marketing the experimental Pfizer-BioNTech mRNA vaccine was granted back in December 2020, [despite the fact that according to the FDA, the vaccine is an](#) “unapproved product”.

[The FDA in an ambiguous statement](#) (see below) has provided a so-called Emergency Use Authorization (EUA) to the Pfizer-BioNTech vaccine, namely “to permit the emergency use of the unapproved product, ... for active immunization...” ([see below](#))

EMERGENCY USE AUTHORIZATION (EUA) OF THE PFIZER-BIONTECH COVID-19 VACCINE TO PREVENT CORONAVIRUS DISEASE 2019 (COVID-19)

The U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) to permit the emergency use of the unapproved product, **Pfizer-BioNTech COVID-19 Vaccine**, for active immunization to prevent COVID-19 in individuals 16 years of age and older.

Injuries and Deaths in the U.S. Attributed to the Pfizer and Moderna mRNA Vaccines

CDC data on “adverse reactions” to the two major Covid mRNA vaccines marketed in the US (Pfizer and Moderna), confirm the incidence of “pulmonary embolism, ... an acute lung disease caused by a dislodged blood clot.” (Brian Shilhalvy, [Vaccine Impact News](#)).

“The CDC is reporting [120 cases of pulmonary embolism](#), including [12 DEATHS](#) following injections of the two experimental COVID mRNA injections currently in the U.S.

Seven of the deaths followed the Moderna mRNA COVID shot, while five deaths followed the Pfizer mRNA COVID shot. (Ibid).

Based on CDC data on deaths and the “adverse reactions”, the suspension of the Pfizer-Moderna mRNA vaccine should be implemented in the United States without delay.

Canada: AstraZeneca, Pfizer and Moderna

Health Canada has given the “Green Light” to all three mRNA vaccines.

Prime Minister Justin Trudeau has reassured Canadians.

“None of the AstraZeneca doses Canada has received are from the batch linked to possible side-effects reported in Europe” ([Canadian Press](#), March 15, 2021).

That’s a nonsensical statement on the part of the Prime Minister: the medicinal ingredients of the Covid-19 AstraZeneca vaccine ([AstraZeneca ChAdOx1-S/nCoV-19 \[recombinant\]](#)), do not vary from one batch to another, or from one country to another.

Update: March 16: 18 European countries have suspended the AstraZeneca vaccine. Yet both Canada’s Prime Minister and Quebec’s Premier François Legault “see no risk associated with the AstraZeneca vaccine.”

“Canada’s National Advisory Committee on Immunization initially recommended that people 65 and over be prioritized for the mRNA vaccines from Pfizer-BioNTech and Moderna because more evidence from trials was available regarding their efficacy on seniors, compared with AstraZeneca’s vaccine.

Both Moderna and Pfizer mRNA vaccines are categorized as “unapproved” and “experimental” in the U.S. by the FDA. (See statement above).

Canadians are Misinformed

The Canadian health authorities have taken AstraZeneca’s PR statements at face value. The documented reports on blood clotting and other “adverse reactions” in EU countries have been casually ignored.

Canada’s Health authorities are concerned that “mixed messaging on AstraZeneca” has contributed to “poisoning the well” of public opinion.

The original source of this article is Global Research
Copyright © [Prof Michel Chossudovsky](#), Global Research, 2021

[Comment on Global Research Articles on our Facebook page](#)

[Become a Member of Global Research](#)

Articles by: [Prof Michel Chossudovsky](#)

About the author:

Michel Chossudovsky is an award-winning author, Professor of Economics (emeritus) at the University of Ottawa, Founder and Director of the Centre for Research on Globalization (CRG), Montreal, Editor of Global Research. He has taught as visiting professor in Western Europe, Southeast Asia, the Pacific and Latin America. He has served as economic adviser to governments of developing countries and has acted as a consultant for several international organizations. He is the author of 13 books. He is a contributor to the Encyclopaedia Britannica. His writings have been published in more than twenty languages. In 2014, he was awarded the Gold Medal for Merit of the Republic of Serbia for his writings on NATO's war of aggression against Yugoslavia. He can be reached at crgeditor@yahoo.com

Disclaimer: The contents of this article are of sole responsibility of the author(s). The Centre for Research on Globalization will not be responsible for any inaccurate or incorrect statement in this article. The Centre of Research on Globalization grants permission to cross-post Global Research articles on community internet sites as long the source and copyright are acknowledged together with a hyperlink to the original Global Research article. For publication of Global Research articles in print or other forms including commercial internet sites, contact: publications@globalresearch.ca

www.globalresearch.ca contains copyrighted material the use of which has not always been specifically authorized by the copyright owner. We are making such material available to our readers under the provisions of "fair use" in an effort to advance a better understanding of political, economic and social issues. The material on this site is distributed without profit to those who have expressed a prior interest in receiving it for research and educational purposes. If you wish to use copyrighted material for purposes other than "fair use" you must request permission from the copyright owner.

For media inquiries: publications@globalresearch.ca